Company news: Burson-Marsteller, Corcept and Orexigen
PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen's net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.
View ArticleCompany news: Vivus and Genentech
Genentech braced for a Boniva patent cliff, only to come up short, and Vivus' branded obesity drug may face immediate generic competition.
View ArticleStudy cites surgery's role in preventing type-2 diabetes
A study says bariatric surgery can keep patients from becoming diabetic. A bariatric surgeon told MM&M that, while the result isn't a surprise, he doesn't expect the findings to cause the number of...
View ArticleFDA, EMA take yo-yo approach on diet pills
Moves by regulators indicate that the yo-yo effect is not just a patient phenomenon, but one that afflicts drugmakers as well.
View ArticleAllergan may shed obesity business, GSK a chairman
The two companies reported third-quarter earnings along with corporate shake-up news.
View ArticleWeight-loss category enters 2013 light on results
The category that saw its first FDA-approved drug in 13 years is still waiting to take off.
View ArticleCompany news: Time, Takeda, Amylin, PwC
Time Inc. targeted media brand focuses on pharma; Takeda and Amylin call it quits on obesity partnership; PricewaterhouseCoopers builds regulatory intelligence unit
View ArticleVivus launches Qsymia weight-loss app
The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.
View ArticleBusiness briefs: HRT, HPV, Novo Nordisk
Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
View ArticleHyperbolic OTC obesity drug ads backfire
When it comes to OTC weight-loss products, deceptive advertising produces diminishing returns, a study has found.
View ArticleAnalysts on Qsymia: show me the payers
Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.
View ArticleBusiness briefs: Arena, Takeda, Teva, Cubist
Arena gets closer to the market place, Takeda scoops up privately held Inviragen, Plan B court decision is coming and Cubist antibotic lands breakthrough therapy status.
View ArticleBusiness Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity
HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
View ArticleOrexigen, Vivus remain in weight-loss limbo
Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.
View ArticleBusiness briefs: AbbVie, AstraZeneca, Valeant, Merck, Novo Nordisk
AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight...
View ArticleWeight-loss category expands by one
Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.
View ArticleBusiness briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
View ArticleBusiness briefs: Alexion, AMA, Eli Lilly
Alexion plans on moving into new HQ in 2015, AMA declares obesity is a disease, FDA looks into Zyprexa patient deaths
View ArticleNovo, Deen agree to suspend their relationship
Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.
View ArticleObesity marketing to stay same, despite new AMA designation
Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.
View Article
More Pages to Explore .....